<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375270</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2010-127</org_study_id>
    <nct_id>NCT01375270</nct_id>
  </id_info>
  <brief_title>Glucolipotoxicity and Type 2 Diabetes</brief_title>
  <official_title>The Effects of Experimental Elevation of Plasma Glucose and Lipid on Pancreatic Beta-cell Function in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevations of blood glucose and lipid are thought to be deleterious to the insulin secretory
      function of the pancreas. This is known as glucolipotoxicity. However, few studies have
      examined this in detail. This investigation will examine pancreatic insulin secretory
      function in physiological models of glucolipotoxicity such as obese and type 2 diabetic
      individuals. Furthermore, healthy subjects will undergo 24 hour infusion of glucose or
      Intralipid to induce experimental models of glucolipotoxicity. Insulin secretion in response
      to intravenous infusions of glucose, GLP-1, GIP, and arginine and in response to meal
      ingestion, will be examined. the investigators hypothesize that experimental
      glucolipotoxicity will impairs pancreatic insulin secretory function to levels akin to that
      seen in type 2 diabetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>24 hours</time_frame>
    <description>Insulin secretion will be assessed in response to intravenous infusions of glucose, GLP-1, GIP, and arginine, and in response to meal ingestion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>24 hours</time_frame>
    <description>Glucose kinetics will be assesed using [6,6-2H2]glucose. Rate of glucose disappearance during glucose infusion will be quantified per unit of plasma insulin to derive an estimate of insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines (IL-6, TNF, IL-1beta, IL-1ra)</measure>
    <time_frame>24 hours</time_frame>
    <description>Cytokines will be measured in plasma: IL-6, TNF-alpha, IL-1beta, IL-1 receptor antagonist, IL-8, IL-10, Interferon gamma. Peripheral blood mononuclear cells will be isolated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glucotoxicity Trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.
The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Trial</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.
The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipotoxicity Trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.
The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glucotoxicity</intervention_name>
    <description>Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.</description>
    <arm_group_label>Glucotoxicity Trial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lipotoxicity</intervention_name>
    <description>Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.</description>
    <arm_group_label>Lipotoxicity Trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal glucose tolerance based on screening OGTT or

          -  diagnosed type 2 diabetic (confirmed with OGTT)

        Exclusion Criteria:

          -  insulin dependent diabetes

          -  age &lt;18 or &gt;65 years

          -  BMI &lt;20 or &gt; 35 kg/m2

          -  evidence of hematological, pulmonary, hepatic, renal, or cardiovascular disease

          -  actively undergoing weight-loss (&gt;2kg change in last 6 months)

          -  bariatric surgery (gastric by-pass or banding)

          -  pregnancy

          -  smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas P Solomon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre of Inflammation and Metabolism, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Solomon</investigator_full_name>
    <investigator_title>Group Leader</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>incretin</keyword>
  <keyword>beta-cell function</keyword>
  <keyword>glucolipotoxicity</keyword>
  <keyword>glucagon-like peptide 1</keyword>
  <keyword>glucose-dependent insulinotropic polypeptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

